Mark C. Rogers, M.D. and Elliott H. Vernon join Procept Inc. Board of Directors

Procept, Inc. (Cambridge, Mass.) has announced the election of Mark C. Rogers, M.D. and Elliott H. Vernon to its board of directors. Their appointments are effective immediately.

Rogers, 55, was most recently senior vice president, CTO at The Perkin-Elmer Corp. From 1992 to 1996, he was the vice chancellor for health affairs at Duke University Medical Center, and executive director and CEO of Duke University Hospital and Health Network. From 1977 to 1992, Rogers was at Johns Hopkins University where he served as a distinguished faculty professor and chairman of the department of anesthesiology and critical care medicine, associate dean for clinical affairs, director of the pediatric intensive care unit and professor of pediatrics. Rogers received his M.D. from Upstate Medical Center, State University of New York and his MBA from the Wharton School of Business. He received a bachelor of arts from Columbia University and held a Fulbright Scholarship.

Vernon, 54, has been the chairman of the board, president and CEO of Healthcare Imaging Services, Inc., a publicly held operator of fixed-site magnetic resonance imaging centers in the northeast, since its inception in 1991. For the past ten years, Vernon has also been the managing partner of MR General Associates, a New Jersey general partnership that is the general partner of DMR Associates, L.P., a Delaware limited partnership. Vernon was also one of the founders of Transworld Nurses, Inc., the predecessor of Transworld HealthCare, Inc., a publicly held regional supplier of a broad range of alternate site healthcare services and products. Vernon is currently a director of Pacific Pharmaceuticals, Inc. a publicly held company engaged in the development and commercialization of medical products, focused primarily on cancer treatment.

"Dr. Rogers and Mr. Vernon bring extensive experience in the healthcare and business communities. Procept will be able to utilize these talents as it accelerates its product development and corporate partnering programs in 1998," said Stanley C. Erck, president and CEO of Procept.

Procept, Inc. is engaged in the research and development of small molecule therapeutics for the prevention and treatment of chronic and life-threatening immune system disorders. Procept is developing therapeutics for the treatment of autoimmune diseases, organ transplant rejection and infectious diseases, such as AIDS and tuberculosis.